In Ja Park1, Jee Yeon Kim2, Chang Sik Yu2, Jong Seok Lee3, Seok-Byung Lim2, Jong Lyul Lee2, Yong Sik Yoon2, Chan Wook Kim2, Jin Cheon Kim2. 1. Department of Colon and Rectal Surgery, University of Ulsan College of Medicine and Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea. ipark@amc.seoul.kr. 2. Department of Colon and Rectal Surgery, University of Ulsan College of Medicine and Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea. 3. Department of Radiology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Abstract
PURPOSE: This retrospective study compared the recurrence-free survival (RFS) and local recurrence rates of patients who received preoperative chemoradiotherapy (PCRT) for cT3N0 vs. those who did not. METHODS: We analyzed the records of 593 patients with transrectal ultrasound (TUS) or magnetic resonance image (MRI)-staged cT3N0 mid and low locally advanced rectal cancer, including 255 who received PCRT and 338 who did not. The RFS and cumulative local recurrence rates were compared in the two groups. We also investigated the rates of pathologic complete response (pCR) and mesorectal lymph node (LN) involvement in the PCRT group. RESULTS: The overall pCR rate was 13.3 %. Of the 338 non-PCRT patients, 125 (37.0 %) had pathologically positive mesorectal LNs. Sphincter-preserving surgery was performed in 431 (72.7 %) of the 593 patients, with similar rates in the two groups. However, the sphincter preservation rate in patients with low rectal cancer was higher among those who received PCRT than among those who did not (64.8 vs. 47 %, P = 0.002). The 5-year RFS (76.4 vs. 75.5 %, P = 0.92) and local recurrence (3.9 vs. 3.0 %, P = 0.97) rates were similar in the PCRT and non-PCRT groups. CONCLUSION: Although PCRT did not improve the RFS or local recurrence rates, it increased the chance of sphincter preservation in patients with low rectal cancer. The advantages of PCRT for patients with cT3N0 should be re-evaluated considering the limitation of pretreatment staging, oncologic benefits, and improved sphincter preservation.
PURPOSE: This retrospective study compared the recurrence-free survival (RFS) and local recurrence rates of patients who received preoperative chemoradiotherapy (PCRT) for cT3N0 vs. those who did not. METHODS: We analyzed the records of 593 patients with transrectal ultrasound (TUS) or magnetic resonance image (MRI)-staged cT3N0 mid and low locally advanced rectal cancer, including 255 who received PCRT and 338 who did not. The RFS and cumulative local recurrence rates were compared in the two groups. We also investigated the rates of pathologic complete response (pCR) and mesorectal lymph node (LN) involvement in the PCRT group. RESULTS: The overall pCR rate was 13.3 %. Of the 338 non-PCRT patients, 125 (37.0 %) had pathologically positive mesorectal LNs. Sphincter-preserving surgery was performed in 431 (72.7 %) of the 593 patients, with similar rates in the two groups. However, the sphincter preservation rate in patients with low rectal cancer was higher among those who received PCRT than among those who did not (64.8 vs. 47 %, P = 0.002). The 5-year RFS (76.4 vs. 75.5 %, P = 0.92) and local recurrence (3.9 vs. 3.0 %, P = 0.97) rates were similar in the PCRT and non-PCRT groups. CONCLUSION: Although PCRT did not improve the RFS or local recurrence rates, it increased the chance of sphincter preservation in patients with low rectal cancer. The advantages of PCRT for patients with cT3N0 should be re-evaluated considering the limitation of pretreatment staging, oncologic benefits, and improved sphincter preservation.
Authors: Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker Journal: Radiology Date: 2004-07-23 Impact factor: 11.105
Authors: Sekhar Dharmarajan; Dandan Shuai; Alyssa D Fajardo; Elisa H Birnbaum; Steven R Hunt; Matthew G Mutch; James W Fleshman; Anne Y Lin Journal: J Gastrointest Surg Date: 2011-05-02 Impact factor: 3.452
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: José G Guillem; Juan A Díaz-González; Bruce D Minsky; Vincenzo Valentini; Seung-Yong Jeong; Miguel A Rodriguez-Bigas; Claudio Coco; Rebecca Leon; José L Hernandez-Lizoain; José J Aristu; Elyn R Riedel; Donato Nitti; W Douglas Wong; Salvatore Pucciarelli Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: Antonio I Picon; Harvey G Moore; Stephen S Sternberg; Bruce D Minsky; Philip B Paty; David Blumberg; Stuart H Quan; W Douglas Wong; Alfred M Cohen; Jose G Guillem Journal: Int J Colorectal Dis Date: 2003-06-03 Impact factor: 2.571
Authors: Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde Journal: Ann Surg Date: 2007-11 Impact factor: 12.969
Authors: Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele Journal: Int J Colorectal Dis Date: 2019-11-27 Impact factor: 2.571